AUB ScholarWorks

Burden of adult community-acquired pneumonia in the Middle East-North Africa region

Show simple item record Shibl A.M. Memish Z.A. Ibrahim E. Kanj S.S.
dc.contributor.editor 2010 2017-10-05T15:39:33Z 2017-10-05T15:39:33Z 2010
dc.identifier 10.1097/MRM.0b013e3283377af7
dc.description.abstract Community-acquired pneumonia (CAP) is a common and often serious disease with substantial morbidity and mortality worldwide. The 2004 World Health Organization Global Burden of Disease Study estimated that lower respiratory tract infections (LRTIs), which include CAP, were responsible for 429.2 million episodes of illness worldwide and were the leading cause of disease burden measured in terms of disability-adjusted life years (DALYs) among all age groups, accounting for 94.5 million DALYs. In adults aged over 59 years, 1.6 million deaths annually are attributed to CAP. LRTIs accounted for 4percent of overall deaths in developed regions of the world, compared with the Middle East-North Africa (MENA) region, where overall mortality due to LRTIs has been reported to be as high as 10percent. The burden of CAP is of even greater concern for aging adults when considering that the number of persons aged over 60 years globally is projected to triple, from 759 million in 2010 to 2 billion by 2050. Streptococcus pneumoniae is the most common pathogen implicated in adult CAP in this region and there is a high level of resistance to penicillin. Increasing resistance to commonly used antibiotics to treat pneumococcal diseases suggests that preventive strategies, including adult vaccination against pneumococcal disease, will be important in the future. The adoption of the recommended Gulf Cooperation Council CAP Working Group guidelines as a standard of care in the MENA region, the development of a regional database to track guideline utilization and clinical outcomes and the strengthening of co-ordinated surveillance through the Eastern Mediterranean Region Surveillance Network will enhance public health efforts to reduce the burden of CAP in adult patients in the MENA region. Future discussions are required to facilitate the implementation of these concepts throughout the region. © 2010 Wolters Kluwer Health I Lippincott Williams and Wilkins.
dc.format.extent Pages: (11-20)
dc.language English
dc.publisher PHILADELPHIA
dc.relation.ispartof Publication Name: Reviews in Medical Microbiology; Publication Year: 2010; Volume: 21; no. 1; Pages: (11-20);
dc.source Scopus
dc.title Burden of adult community-acquired pneumonia in the Middle East-North Africa region
dc.type Article
dc.contributor.affiliation Shibl, A.M., Department of Microbiology, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia
dc.contributor.affiliation Memish, Z.A., King Abdulaziz Medical City, Riyadh, Saudi Arabia
dc.contributor.affiliation Ibrahim, E., Alexandria College of Medicine, Alexandria, Egypt
dc.contributor.affiliation Kanj, S.S., American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.authorAddress Shibl, A. M.; Department of Microbiology, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia; email:
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Shibl, AM
dc.contributor.authorInitials Memish, ZA
dc.contributor.authorInitials Ibrahim, E
dc.contributor.authorInitials Kanj, SS
dc.contributor.authorReprintAddress Shibl, AM (reprint author), King Saud Univ, Dept Microbiol, POB 2457, Riyadh 11451, Saudi Arabia.
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Abdel-Rahman EM, 2000, DIAGN MICR INFEC DIS, V36, P203, DOI 10.1016-S0732-8893(99)00142-X; Ahmad S, 2009, JCPSP-J COLL PHYSICI, V19, P264, DOI 04.2009-JCPSP.264265; Ahmed K, 2000, EPIDEMIOL INFECT, V125, P573, DOI 10.1017-S0950268800004751; AHMED K, 1999, J INFECT CHEMOTHER, V5, P217, DOI 10.1007-s101560050039; Akala FA, 2006, LANCET, V367, P961, DOI 10.1016-S0140-6736(06)68402-X; Akbar DH, 2001, ACTA DIABETOL, V38, P77; ALALI MK, 2007, SAUDI MED J, V28, P813; Al-Ghamdi SM, 2003, SAUDI MED J, V24, P1073; Al-Ghizawi G. J., 2007, Eastern Mediterranean Health Journal, V13, P230; Al-Moyed K A, 2003, East Mediterr Health J, V9, P279; Al-Muhairi S, 2006, Monaldi Arch Chest Dis, V65, P13; Al-Muhairi SS, 2006, SAUDI MED J, V27, P1044; Alzeer A, 1998, J INFECTION, V36, P303, DOI 10.1016-S0163-4453(98)94315-8; Babay HA, 2000, SAUDI MED J, V21, P860; Balkhy HH, 2006, INT J INFECT DIS, V10, P326, DOI 10.1016-j.ijid.2005.06.013; Behbehani N, 2005, MED PRIN PRACT, V14, P235, DOI 10.1159-000085741; BISHAY FK, RURAL DEV POVERTY ME; Boutiba-Ben Boubaker I, 1998, Tunis Med, V76, P380; Cherfan AJ, 2003, AM J HEALTH-SYST PH, V60, P934; ELSHAFIE SS, 2004, INT J ANTIMICROB AG, V24, P111; HAMBORSKY J, 2008, MMWR-MORBID MORTAL W, V57, P1148; Hanssens Y, 2005, SAUDI MED J, V26, P1269; Hausdorff WP, 2007, VACCINE, V25, P1935, DOI 10.1016-j.vaccine.2006.11.018; Hussain Syed Fayyaz, 2006, J Coll Physicians Surg Pak, V16, P287; Irfan Muhammad, 2009, JPMA Journal of the Pakistan Medical Association, V59, P448; Kanj SS, 2007, INT J INFECT DIS, V11, P554, DOI 10.1016-j.ijid.2007.01.012; KURASHI NY, 1992, THORAX, V47, P115, DOI 10.1136-thx.47.2.115; Madani TA, 2007, ANN SAUDI MED, V27, P101, DOI 10.4103-0256-4947.51528; McIvor RA, 2004, CHEST, V126, P1015, DOI 10.1378-chest.126.4.1015; Memish Z A, 2007, J Chemother, V19 Suppl 1, P7; Memish Z A, 2007, J Chemother, V19 Suppl 1, P17; Memish ZA, 2004, INT J ANTIMICROB AG, V23, P32, DOI 10.1016-j.ijantimicag.2003.05.008; Memish Z A, 2007, J Chemother, V19 Suppl 1, P25; Memish Z A, 2007, J Chemother, V19 Suppl 1, P33; Mikaeilli H, 2009, Pak J Biol Sci, V12, P514, DOI 10.3923-pjbs.2009.514.517; Mokaddas EM, 2007, MICROB DRUG RESIST, V13, P227, DOI 10.1089-mdr.2007.774; Mokaddas EM, 2008, CLIN VACCINE IMMUNOL, V15, P203, DOI 10.1128-CVI.00277-07; Mokaddas EM, 2001, J CHEMOTHERAPY, V13, P154; Querol-Ribelles JM, 2004, CHEST, V126, P1087, DOI 10.1378-chest.126.4.1087; Ramdani-Bouguessa N, 2003, ANTIMICROB AGENTS CH, V47, P824, DOI 10.1128-AAC.47.2.824-826.2003; SCHRAG S, 2001, WHOCDSCSRDRS20016; *UN DEP EC SOC AFF, ESAPWP210; WHO, GLOB BURD DIS 2004 U; *WHO DIV COMM DIS, 2006, DCD NEWSLETT; *WORLD BANK, MIDDL E N AFR COUNTR; *WORLD BANK, REP YEM COMPR DEV RE; Yousuf M, 1995, ANN SAUDI MED, V15, P619; Zuberi FF, 2008, INT J TUBERC LUNG D, V12, P447; 2005, LANCET, V365, P1204
dc.description.citedCount 1
dc.description.citedTotWOSCount 1
dc.description.citedWOSCount 1
dc.format.extentCount 10
dc.identifier.coden RMEME
dc.identifier.scopusID 79955808735
dc.publisher.address 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
dc.relation.ispartOfISOAbbr Rev. Med. Microbiol.
dc.relation.ispartOfIssue 1
dc.relation.ispartofPubTitle Reviews in Medical Microbiology
dc.relation.ispartofPubTitleAbbr Rev. Med. Microbiol.
dc.relation.ispartOfVolume 21
dc.source.ID WOS:000275134100003
dc.type.publication Journal
dc.subject.otherAuthKeyword adult
dc.subject.otherAuthKeyword burden
dc.subject.otherAuthKeyword community-acquired pneumonia
dc.subject.otherAuthKeyword Middle East-North Africa
dc.subject.otherChemCAS amoxicillin, 26787-78-0, 34642-77-8, 61336-70-7
dc.subject.otherChemCAS amoxicillin plus clavulanic acid, 74469-00-4, 79198-29-1
dc.subject.otherChemCAS ampicillin, 69-52-3, 69-53-4, 7177-48-2, 74083-13-9, 94586-58-0
dc.subject.otherChemCAS carbapenem, 83200-96-8
dc.subject.otherChemCAS cefaclor, 53994-73-3
dc.subject.otherChemCAS cefotaxime, 63527-52-6, 64485-93-4
dc.subject.otherChemCAS cefoxitin, 33564-30-6, 35607-66-0
dc.subject.otherChemCAS ceftazidime, 72558-82-8
dc.subject.otherChemCAS ceftriaxone, 73384-59-5, 74578-69-1
dc.subject.otherChemCAS cefuroxime, 55268-75-2, 56238-63-2
dc.subject.otherChemCAS cephalosporin, 11111-12-9
dc.subject.otherChemCAS chloramphenicol, 134-90-7, 2787-09-9, 56-75-7
dc.subject.otherChemCAS ciprofloxacin, 85721-33-1
dc.subject.otherChemCAS clindamycin, 18323-44-9
dc.subject.otherChemCAS cotrimoxazole, 8064-90-2
dc.subject.otherChemCAS erythromycin, 114-07-8, 70536-18-4
dc.subject.otherChemCAS gatifloxacin, 112811-59-3, 180200-66-2
dc.subject.otherChemCAS imipenem, 64221-86-9
dc.subject.otherChemCAS levofloxacin, 100986-85-4, 138199-71-0
dc.subject.otherChemCAS linezolid, 165800-03-3
dc.subject.otherChemCAS oxacillin, 1173-88-2, 66-79-5, 7240-38-2
dc.subject.otherChemCAS penicillin G, 1406-05-9, 61-33-6
dc.subject.otherChemCAS tetracycline, 23843-90-5, 60-54-8, 64-75-5, 8021-86-1
dc.subject.otherChemCAS tobramycin, 32986-56-4
dc.subject.otherChemCAS trimethoprim, 738-70-5
dc.subject.otherChemCAS vancomycin, 1404-90-6, 1404-93-9
dc.subject.otherIndex amoxicillin
dc.subject.otherIndex amoxicillin plus clavulanic acid
dc.subject.otherIndex ampicillin
dc.subject.otherIndex antibiotic agent
dc.subject.otherIndex carbapenem
dc.subject.otherIndex cefaclor
dc.subject.otherIndex cefotaxime
dc.subject.otherIndex cefoxitin
dc.subject.otherIndex ceftazidime
dc.subject.otherIndex ceftriaxone
dc.subject.otherIndex cefuroxime
dc.subject.otherIndex cephalosporin
dc.subject.otherIndex chloramphenicol
dc.subject.otherIndex ciprofloxacin
dc.subject.otherIndex clindamycin
dc.subject.otherIndex cotrimoxazole
dc.subject.otherIndex erythromycin
dc.subject.otherIndex gatifloxacin
dc.subject.otherIndex imipenem
dc.subject.otherIndex levofloxacin
dc.subject.otherIndex linezolid
dc.subject.otherIndex macrolide
dc.subject.otherIndex oxacillin
dc.subject.otherIndex penicillin G
dc.subject.otherIndex quinoline derived antiinfective agent
dc.subject.otherIndex tetracycline
dc.subject.otherIndex tobramycin
dc.subject.otherIndex trimethoprim
dc.subject.otherIndex unindexed drug
dc.subject.otherIndex vancomycin
dc.subject.otherIndex aging
dc.subject.otherIndex antibiotic resistance
dc.subject.otherIndex antibiotic sensitivity
dc.subject.otherIndex article
dc.subject.otherIndex Chlamydophila pneumoniae
dc.subject.otherIndex community acquired pneumonia
dc.subject.otherIndex Haemophilus influenzae
dc.subject.otherIndex hospital admission
dc.subject.otherIndex human
dc.subject.otherIndex Influenza virus A
dc.subject.otherIndex Influenza virus B
dc.subject.otherIndex Klebsiella pneumoniae
dc.subject.otherIndex Lebanon
dc.subject.otherIndex Legionella pneumophila
dc.subject.otherIndex length of stay
dc.subject.otherIndex lower respiratory tract infection
dc.subject.otherIndex lung burden
dc.subject.otherIndex Middle East
dc.subject.otherIndex mixed infection
dc.subject.otherIndex Moraxella catarrhalis
dc.subject.otherIndex morbidity
dc.subject.otherIndex mortality
dc.subject.otherIndex Mycobacterium tuberculosis
dc.subject.otherIndex Mycoplasma pneumoniae
dc.subject.otherIndex nonhuman
dc.subject.otherIndex North Africa
dc.subject.otherIndex Parainfluenza virus
dc.subject.otherIndex pathogenesis
dc.subject.otherIndex priority journal
dc.subject.otherIndex Pseudomonas aeruginosa
dc.subject.otherIndex Respiratory syncytial pneumovirus
dc.subject.otherIndex risk factor
dc.subject.otherIndex Staphylococcus aureus
dc.subject.otherIndex Streptococcus
dc.subject.otherIndex Streptococcus pneumoniae
dc.subject.otherKeywordPlus PLASMA D-DIMER
dc.subject.otherKeywordPlus SAUDI-ARABIA
dc.subject.otherKeywordPlus ANTIMICROBIAL RESISTANCE
dc.subject.otherKeywordPlus ANTIBIOTIC-RESISTANCE
dc.subject.otherKeywordPlus SEROTYPE DISTRIBUTION
dc.subject.otherKeywordPlus MEDICAL-CENTER
dc.subject.otherKeywordPlus NORTH-AFRICA
dc.subject.otherKeywordPlus PREVALENCE
dc.subject.otherKeywordPlus KUWAIT
dc.subject.otherWOS Microbiology

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account